{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T07:55:47Z","timestamp":1793087747634,"version":"4.5.0"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T00:00:00Z","timestamp":1747958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The strategy for eliminating viral hepatitis is at a critical juncture, necessitating an updated assessment of global incidence trends.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data on the incidence of four types of acute viral hepatitis (AVH), namely, acute hepatitis A (AHA), acute hepatitis B (AHB), acute hepatitis C (AHC), and acute hepatitis E (AHE), were sourced from the Global Burden of Disease (GBD) Study 2021. The annual percentage change is utilized to elucidate temporal trends, whereas health inequalities and frontier analysis serve to evaluate global health equity and quantify disparities in burden among countries.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In 2021, the estimated global incidence for AVH was as follows: AHA (160.86 million), AHB (63.53 million), AHE (19.37 million), and AHC (7.01 million). From 2000 to 2021, the age-standardized incidence rates (ASIR) for four types of AVH demonstrated a declining trend, with AHB showing the most significant decrease. It is anticipated that the incidence rates for AHA, AHB, and AHC will continue to decline over the next 15\u202fyears; however, the incidence rate of AHE is projected to increase. In 2021, the incidence of AVH displayed a significant negative correlation with the Socio-Demographic Index (SDI), but health disparities between countries have diminished. Countries with the highest potential for elimination of AHB are primarily situated in low and low-middle SDI regions, whereas those for AHA are concentrated in high and high-middle SDI regions. Furthermore, countries with the largest disparities in AHC and AHE were dispersed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Although global incidence of AVH is decreasing, it remains a serious public health challenge. Reducing health disparities is crucial for the elimination of viral hepatitis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpubh.2025.1580863","type":"journal-article","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T01:30:49Z","timestamp":1747963849000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Update on the global burden of acute viral hepatitis in 2021: addressing health inequalities"],"prefix":"10.3389","volume":"13","author":[{"given":"Lei","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengpeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuanghua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,23]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.1111\/liv.15452","article-title":"Incidence trends of acute viral hepatitis caused by four viral etiologies between 1990 and 2019 at the global, regional and national levels","volume":"42","author":"Ouyang","year":"2022","journal-title":"Liver Int"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1111\/liv.15514","article-title":"Viral hepatitis elimination challenges in low-and middle-income countries-Uzbekistan hepatitis elimination program (UHEP)","volume":"43","author":"Musabaev","year":"2023","journal-title":"Liver Int"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.jhep.2019.05.011","article-title":"Hepatitis a and E-differences and commonalities","volume":"72","author":"Gotlieb","year":"2020","journal-title":"J Hepatol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1093\/clinids\/20.4.992","article-title":"Risks of chronicity following acute hepatitis B virus infection: a review","volume":"20","author":"Hyams","year":"1995","journal-title":"Clin Infect Dis"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/j.1365-2893.2005.00651.x","article-title":"Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies","volume":"13","author":"Micallef","year":"2006","journal-title":"J Viral Hepat"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1111\/jvh.12866","article-title":"Assessing hepatitis C spontaneous clearance and understanding associated factors-a systematic review and meta-analysis","volume":"25","author":"Aisyah","year":"2018","journal-title":"J Viral Hepat"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.jhep.2023.05.001","article-title":"EASL clinical practice guidelines on hepatitis delta virus","volume":"79","year":"2023","journal-title":"J Hepatol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/s2468-1253(22)00050-4","article-title":"Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: a systematic review","volume":"7","author":"Alberts","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41575-021-00570-x","article-title":"Vaccination at the forefront of the fight against hepatitis B and C","volume":"19","author":"El-Sayed","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref10","article-title":"WHO Hepatitis A Vaccine Global Market Study","year":"2023"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3390\/vaccines13010028","article-title":"Immunogenicity, efficacy, and effectiveness of two-dose and shorter schedules of hepatitis E vaccine: a systematic review","volume":"13","author":"Azam","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3390\/diagnostics15020123","article-title":"Impact of point-of-care testing on diagnosis, treatment, and surveillance of vaccine-preventable viral infections","volume":"15","author":"Lakshmanan","year":"2025","journal-title":"Diagnostics (Basel)"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.jhep.2021.11.024","article-title":"How to achieve functional cure of HBV: stopping NUCs, adding interferon or new drug development?","volume":"76","author":"Wong","year":"2022","journal-title":"J Hepatol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/s2468-1253(22)00386-7","article-title":"Global reporting of progress towards elimination of hepatitis B and hepatitis C. Lancet","volume":"8","author":"Cui","year":"2023","journal-title":"Gastroenterol Hepatol"},{"key":"ref15","volume-title":"Combating hepatitis B and C to reach elimination by 2030: Advocacy brief","year":"2016"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/s41575-023-00760-9","article-title":"Global burden of hepatitis B virus: current status, missed opportunities and a call for action","volume":"20","author":"Hsu","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"4959","DOI":"10.3748\/wjg.v24.i44.4959","article-title":"Hepatitis elimination by 2030: progress and challenges","volume":"24","author":"Waheed","year":"2018","journal-title":"World J Gastroenterol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1016\/s0140-6736(24)00757-8","article-title":"Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the global burden of disease study 2021","volume":"403","year":"2024","journal-title":"Lancet"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.jhep.2021.04.035","article-title":"Global burden of acute viral hepatitis and its association with socioeconomic development status, 1990-2019","volume":"75","author":"Zeng","year":"2021","journal-title":"J Hepatol"},{"key":"ref20","volume-title":"Handbook on health inequality monitoring: With a special focus on low-and middle-income countries","year":"2013"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.medj.2024.04.009","article-title":"Global pattern, trend, and cross-country inequality of early musculoskeletal disorders from 1990 to 2019, with projection from 2020 to 2050","volume":"5","year":"2024","journal-title":"Med"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/s0140-6736(17)30818-8","article-title":"Healthcare access and quality index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990-2015: a novel analysis from the global burden of disease study 2015","volume":"390","year":"2017","journal-title":"Lancet"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/(sici)1097-0258(20000215)19:3<335::aid-sim336>3.0.co;2-z","article-title":"Permutation tests for joinpoint regression with applications to cancer rates","volume":"19","author":"Kim","year":"2000","journal-title":"Stat Med"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40880-018-0282-3","article-title":"Cancer mortality in Serbia, 1991-2015: an age-period-cohort and joinpoint regression analysis","volume":"38","author":"Ilic","year":"2018","journal-title":"Cancer Commun (Lond)"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/s2352-4642(23)00148-7","article-title":"Burden of non-communicable diseases among adolescents and young adults aged 10-24 years in the South-East Asia and Western Pacific regions, 1990-2019: a systematic analysis for the global burden of disease study 2019","volume":"7","author":"Wang","year":"2023","journal-title":"Lancet Child Adolesc Health"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"135319","DOI":"10.1016\/j.jhazmat.2024.135319","article-title":"Global, regional, and national burden of cancers attributable to particulate matter pollution from 1990 to 2019 and projection to 2050: worsening or improving?","volume":"477","author":"Chen","year":"2024","journal-title":"J Hazard Mater"},{"key":"ref27","volume-title":"Global hepatitis report 2024: Action for access in low-and middle-income countries","year":"2024"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1016\/s0140-6736(98)01304-x","article-title":"Hepatitis a","volume":"351","author":"Koff","year":"1998","journal-title":"Lancet"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.vaccine.2021.01.038","article-title":"One or two doses of hepatitis a vaccine in universal vaccination programs in children in 2020: a systematic review","volume":"40","author":"Andani","year":"2022","journal-title":"Vaccine"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1080\/21645515.2016.1242539","article-title":"Impact of universal mass vaccination with monovalent inactivated hepatitis a vaccines - a systematic review","volume":"13","author":"Stuurman","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"ref31","article-title":"Hepatitis A Vaccines: WHO Position Paper","year":"2022"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1001\/jama.2022.18474","article-title":"WHO backs single dose of hepatitis a vaccine in some cases","volume":"328","author":"Larkin","year":"2022","journal-title":"JAMA"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1099\/jgv.0.001435","article-title":"Update: proposed reference sequences for subtypes of hepatitis E virus (species Orthohepevirus a)","volume":"101","author":"Smith","year":"2020","journal-title":"J Gen Virol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/s1473-3099(08)70255-x","article-title":"Hepatitis E: an emerging infection in developed countries","volume":"8","author":"Dalton","year":"2008","journal-title":"Lancet Infect Dis"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.cmi.2020.03.039","article-title":"Hepatitis E: an expanding epidemic with a range of complications","volume":"26","author":"Webb","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.jinf.2016.06.005","article-title":"Clinical and virological profiling of sporadic hepatitis E virus infection in China","volume":"73","author":"Wang","year":"2016","journal-title":"J Infect"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1186\/s12884-020-03116-2","article-title":"Burden of hepatitis E virus infection in pregnancy and maternofoetal outcomes: a systematic review and meta-analysis","volume":"20","author":"Bigna","year":"2020","journal-title":"BMC Pregnancy Childbirth"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/s0140-6736(23)02234-1","article-title":"Long-term efficacy of a recombinant hepatitis E vaccine in adults: 10-year results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"403","author":"Huang","year":"2024","journal-title":"Lancet"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"e1288","DOI":"10.1016\/s2214-109x(24)00192-x","article-title":"Safety and effectiveness of a recombinant hepatitis E vaccine in women of childbearing age in rural Bangladesh: a phase 4, double-blind, cluster-randomised, controlled trial","volume":"12","author":"Zaman","year":"2024","journal-title":"Lancet Glob Health"},{"key":"ref40","volume-title":"Meeting of the strategic advisory Group of Experts on immunization, march 2024: Conclusions and recommendations","year":"2024"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/S0140-6736(16)30579-7","article-title":"The global burden of viral hepatitis from 1990 to 2013: findings from the global burden of disease study 2013","volume":"388","author":"Stanaway","year":"2016","journal-title":"Lancet"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/s2468-1253(23)00197-8","article-title":"Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study","volume":"8","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref43","article-title":"Hepatitis B vaccination coverage","year":""},{"key":"ref44","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/s2468-1253(17)30295-9","article-title":"Hepatitis B in sub-Saharan Africa: strategies to achieve the 2030 elimination targets","volume":"2","author":"Spearman","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"S53","DOI":"10.1038\/d41586-022-00815-y","article-title":"Simplify access to hepatitis B care","volume":"603","author":"Hellard","year":"2022","journal-title":"Nature"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"623","DOI":"10.3350\/cmh.2022.0349","article-title":"Acute hepatitis C virus infection: clinical update and remaining challenges","volume":"29","author":"Liu","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"465","DOI":"10.15585\/mmwr.mm6618a2","article-title":"State HCV incidence and policies related to HCV preventive and treatment Services for Persons who Inject Drugs-United States, 2015-2016","volume":"66","author":"Campbell","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/s2468-1253(21)00472-6","article-title":"Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study","volume":"7","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"637","DOI":"10.7326\/m16-2575","article-title":"Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review","volume":"166","author":"Falade-Nwulia","year":"2017","journal-title":"Ann Intern Med"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/s2468-1253(23)00408-9","article-title":"WHO hepatitis C elimination targets: the global equity challenge","volume":"9","author":"Heath","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1136\/bmj.p2353","article-title":"Hepatitis C: Egypt makes \"unprecedented progress\" towards elimination","volume":"383","author":"Mahase","year":"2023","journal-title":"BMJ"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1093\/jtm\/taae020","article-title":"Elimination of hepatitis C in Egypt: unprecedented achievement despite challenges","volume":"31","author":"Saied","year":"2024","journal-title":"J Travel Med"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1001\/jama.2023.3692","article-title":"A National Hepatitis C Elimination Program in the United States: a historic opportunity","volume":"329","author":"Fleurence","year":"2023","journal-title":"JAMA"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1580863\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T01:30:51Z","timestamp":1747963851000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1580863\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,23]]},"references-count":53,"alternative-id":["10.3389\/fpubh.2025.1580863"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2025.1580863","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,23]]},"article-number":"1580863"}}